Cannabis Drug Shows Promise in Treating Schizophrenia

An experimental cannabis drug for treating schizophrenia, developed by UK-based GW Pharmaceuticals Plc, was found to be superior to a placebo in a mid-stage trial.

The company’s UK-listed shares jumped 12.5 percent, while U.S.-listed shares were up 10 pct.

The drug, cannabidiol, was tested in 88 patients with schizophrenia, who had failed to respond to anti-psychotic medication.

During the trial, patients remained on their anti-psychotic medication and received doses of either cannabidiol or a placebo, the company said in a statement

GW is testing its cannabis drugs for a number of indications, including cancer-related pain and epilepsy.